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Abstract
Background: Our previous research found that structural changes of the microtubule network influence glycolysis in
cardiomyocytes by regulating the hypoxia-inducible factor (HIF)-1a during the early stages of hypoxia. However, little is
known about the underlying regulatory mechanism of the changes of HIF-1a caused by microtubule network alternation.
The von Hippel-Lindau tumor suppressor protein (pVHL), as a ubiquitin ligase, is best understood as a negative regulator of
HIF-1a.
Methodology/Principal Findings: In primary rat cardiomyocytes and H9c2 cardiac cells, microtubule-stabilization was
achieved by pretreating with paclitaxel or transfection of microtubule-associated protein 4 (MAP4) overexpression plasmids
and microtubule–depolymerization was achieved by pretreating with colchicine or transfection of MAP4 siRNA before
hypoxia treatment. Recombinant adenovirus vectors for overexpressing pVHL or silencing of pVHL expression were
constructed and transfected in primary rat cardiomyocytes and H9c2 cells. With different microtubule-stabilizing and -
depolymerizing treaments, we demonstrated that the protein levels of HIF-1a were down-regulated through
overexpression of pVHL and were up-regulated through knockdown of pVHL in hypoxic cardiomyocytes. Importantly,
microtubular structure breakdown activated p38/MAPK pathway, accompanied with the upregulation of pVHL. In
coincidence, we found that SB203580, a p38/MAPK inhibitor decreased pVHL while MKK6 (Glu) overexpression increased
pVHL in the microtubule network altered-hypoxic cardiomyocytes and H9c2 cells.
Conclusions/Significance: This study suggests that pVHL plays an important role in the regulation of HIF-1a caused by the
changes of microtubular structure and the p38/MAPK pathway participates in the process of pVHL change following
microtubule network alteration in hypoxic cardiomyocytes.
Citation: Teng M, Jiang X-p, Zhang Q, Zhang J-p, Zhang D-x, et al. (2012) Microtubular Stability Affects pVHL-Mediated Regulation of HIF-1alpha via the p38/
MAPK Pathway in Hypoxic Cardiomyocytes. PLoS ONE 7(4): e35017. doi:10.1371/journal.pone.0035017
Editor: Ferenc Gallyas, University of Pecs Medical School, Hungary
Received November 2, 2011; Accepted March 8, 2012; Published April 10, 2012
Copyright:  2012 Teng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Program of National Natural Science Foundation of China (No. 81101425 and No. 81055748), Key Project of
China National Programs for Basic Research and Development (No. 2012CB518101), and Science Foundation of the Third Military Medical University (No.
2010XQN24). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: yshuang.tmmu@gmail.com
. These authors contributed equally to this work.
Introduction
Hypoxia is a common pathophysiological process in many
human diseases. Despite being a frequent process in the human
system, the hypoxic state is implicated in the onset and progression
of many life-threatening diseases. Myocardial hypoxia is a
common clinical finding in patients with coronary artery disease,
hypertensive heart disease and cardiomyopathy [1,2]. Interesting-
ly, this particular type of tissue damage is also present in patients
with severe burns [3,4]. At the cellular level hypoxia or ischemia
elicits cytoskeletal damage, including microtubule network alter-
ation [5,6]. This alteration in the sub-cellular architecture in turn
influences glycolysis in hypoxic cardiomyocytes (CMs), a process
mediated by hypoxia-inducible factor (HIF)-1a [7], which is itself
regulated by O2 tension and the microtubule network [7–9].
The microtubule network is a major component of the
eukaryotic cytoskeleton and has multiple effects on cellular
processes. Previous studies have suggested that microtubule-
stabilizing agent (paclitaxel) or transfection of physiological
microtubule stabilizer (MAP4) stabilizes microtubules [7,10,11]
and up-regulates HIF-1a in CMs during early hypoxia [7]. In
addition, cytoskeletal disruption also results in increased expres-
sion of pVHL in renal cell carcinoma cells during hypoxia [12].
pVHL is encoded by a tumor-suppressor gene located on
chromosome 3p25 and functions as the E3 ubiquitin ligase for
HIF-1a [13,14]. pVHL-mediated ubiquitination of HIF-1a plays a
central role in the cellular responses to changes in oxygen
availability [15–17]. Under normoxic conditions, HIF-1a is
rapidly degraded by the pVHL-mediated ubiquitin-proteasome
pathway [18]. Conversely, under hypoxic conditions, HIF-1a is
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[19,20].
It is well known that microtubules play a key role in signal
transduction [21]. Mitogen-activated protein kinase (MAPK)
systems, especially p38/MAPK, are involved in the intracellular
signaling events triggered by microtubule-interfering agents [22–
24]. Recent data showed that phospho-p38 could be co-
immunoprecipitated with MAP4 in normoxic and hypoxic CMs
[5]. In addition, p38/MAPK modulates the expression of HIF-1a
[25,26] and pVHL [12] in hypoxic cells. Accordingly, these data
promoted us to investigate the functions of p38/MAPK in the
regulation of pVHL following microtubule alteration.
Moreover, microtubule stabilization regulates HIF-1a [7–9] and
pVHL protein levels [12], and the affinity of HIF-1a toward pVHL
decreases during hypoxia [19,20]. Little is known about the
regulationofHIF-1amediated by pVHL after microtubule alteration
during early hypoxia. Here, we report that pVHL is involved in the
regulation of HIF-1a in response to both microtubule stabilization
and disruption and that the p38/MAPK pathway plays an important
role in regulating pVHL during early hypoxia. Our results suggest
that, in both hypoxic CMs and H9c2 cells, microtubular stabilization
decreases the activity of the p38/MAPK pathway, which in turn
suppresses pVHL and leads to the up-regulation of HIF-1a.T h u s ,
our findings provide novel insights into the regulation of HIF-1a by
microtubule alternation in hypoxic CMs.
Results
Effects of microtubule network alteration on HIF-1a
protein levels in normoxic cardiomyocytes
Cardiomyocytes and H9c2 cells cultured under normoxic
conditions were exposed to microtubule-stabilization treatments
(paclitaxel, or transfection of MAP4 overexpression plasmids), or
microtubule–depolymerization treatments (colchicine, or transfec-
tion of MAP4 siRNA). The changes in HIF-1a protein levels were
detected in treated and untreated cells by Western blotting. The
results showed that the HIF-1a protein levels were low under
normoxic conditions, and none of the treatments with microtu-
bule-interfering agents produced any change in the HIF-1a
protein levels (Figure S1).
Microtubule network alteration of hypoxic
cardiomyocytes resulted in change of pVHL protein
levels
When subjected to hypoxic conditions, the microtubule network
in CMs and H9c2 cells became disordered. Microtubular shrinkage
was observed in the vicinity of the nuclei and the microtubules
appeared to curl and buckle along the edges of the cells (Figure 1A).
MAP4 is an endogenous stabilizer of microtubules [10]. To change
microtubule network, we used paclitaxel and colchicine as well as
vectors to increase or decrease MAP4. The protein levels of MAP4
increased in hypoxic CMs and H9c2 cells transfected with MAP4
recombinant adenovirus and decreased in hypoxic cells transfected
with MAP4-siRNA adenovirus (Figure 1B and 1C). Overexpression
of MAP4 or pretreatment with paclitaxel restabilized the
microtubule network of the hypoxic CMs and H9c2 cells.
Specifically, the reticular microtubules appeared as bundled and
evenly distributed in the cytoplasm and the microtubule density
was significantly higher than that in control group. In contrast,
knockdown of MAP4 by siRNA or pretreatment with colchicine
further disrupted the microtubule network of the hypoxic cells and
the microtubule density was low(Figure 1A).
We next evaluated the pVHL protein levels in those cells with
altered microtubule networks. Under hypoxic conditions, micro-
tubule stabilization decreased the protein levels of pVHL, while
depolymerization of the microtubules increased it (Figure 1D and
1E).
Involvement of pVHL in the regulation of HIF-1a
following microtubule alteration
It is well documented that microtubule network alteration leads
to appreciable changes in HIF-1a levels [7–9]. We sought to
determine whether this alteration of HIF-1a protein levels depends
on the microtubule alteration-induced pVHL change. CMs and
H9c2 cells were transfected with pVHL recombinant adenovirus
to overexpress pVHL or pVHL-siRNA adenovirus to knockdown
pVHL prior to microtubule interference, after which the cells were
subjected to hypoxic conditions as described. In both CMs and
H9c2 cells, the protein levels of HIF-1a were down-regulated by
pVHL overexpression and up-regulated by knockdown of pVHL.
In contrast, cells expressing GFP showed no changes in HIF-1a
protein levels compared to the control group (Figure 2). These
results suggested that pVHL plays an important role in the
regulation of HIF-1a after alteration of the microtubule network in
hypoxic CMs and H9c2 cells.
Microtubule network depolymerization of hypoxic
cardiomyocytes activated p38/MAPK signaling pathway
To elucidate the signaling events of microtubule alteration-
induced pVHL change, we investigated the status of the p38/
MAPK signaling pathway in hypoxic CMs and H9c2 cells.
Phospho-p38 in hypoxic CMs and H9c2 cells was found by
immunoblotting to be elevated significantly in response to
knockdown of MAP4 or pretreatment with colchicine. While in
microtubule-stabilized hypoxic cells, pretreatment with MAP4
recombinant adenovirus or paclitaxel decreased phospho-p38, as
compared to that in control group. (Figure 3).
Microtubule alteration-induced change of pVHL relied on
p38/MAPK signaling
To test whether the changes of pVHL induced by microtubule
alteration depend on the activity of p38/MAPK, we treated CMs
and H9c2 cells with the p38/MAPK inhibitor SB203580.
SB203580 downregulated pVHL in the hypoxic cells pretreated
with either paclitaxel or colchicine (Figure 4). We then further
overexpressed p38 kinase activator MKK6 (Glu) in these cells.
MKK6 is known to phosphorylate p38/MAPK on Thr-180 and
Tyr-182, which leads to the activation of p38/MAPK [27]. The
cells were transfected with MKK6 (Glu) recombinant adenoviruses
before pretreating with microtubule interfering agents (paclitaxel
or colchicine). Three hours after hypoxia, pVHL was found to
have increased significantly and no changes were observed in the
cells expressing GFP (Figure 5). These results indicated that p38/
MAPK signaling plays an important role in the change of pVHL
protein levels in hypoxic CMs after microtubule alteration.
Phospho-p38 physically interacts with a-tubulin
The microtubule interfering agents (paclitaxel or colchicine) are
well-documented for their ability to change the microtubule
network through interaction with a/b-tubulin heterodimers [28].
The microtubule network alteration induced by paclitaxel or
colchicine may affect the p38/MAPK signaling pathway by
forming a complex with a-tubulin. We tested this hypothesis by
immunoprecipitation. In both CMs and H9c2 cells pretreated with
paclitaxel or colchicine, a-tubulin was co-immunoprecipitated by
phospho-p38. Conversely, phospho-p38 could be co-immunopre-
cipitated by a-tubulin under hypoxic conditions (Figure 6).
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The microtubule network is a major component of the
cytoskeleton and is crucial for the maintenance of normal cellular
physiology. We previously found that microtubule interference
affects glycolysis of CMs during early hypoxia through regulation
of HIF-1a, and HIF-1a content in response to hypoxic
microtubular structural changes occured only at the post-
transcriptional level [7]. However, little is known about how such
a microtubule network alteration results in the change of HIF-1a
Figure 1. Microtubule network alteration of hypoxic cardiomyocytes resulted in change of pVHL protein levels. (A)
Immunofluorescent confocal micrographs. a-tubulin is green and the nucleus is blue. N, normoxia; H, hypoxia; H+P, hypoxia and paclitaxel;
H+MAP4, hypoxia and MAP4 overexpression; H+HK1, hypoxia and a HK plasmid (as a negative control of MAP4 transfection); H+C, hypoxia and
colchicine; H+siRNA, hypoxia and transfected for MAP4-siRNA; H+HK2, hypoxia and a HK plasmid (as a negative control of MAP4-siRNA). (B) Western
blots showing MAP4 protein expression for the various experimental groups. (C, E) Graphs representing the mean6SD (n=5) of the relative
integrated signal. (D) Western blot analysis of pVHL in microtubule-altered hypoxic cardiomyocytes and H9c2 cells. DP,0.05 vs. Hypoxia group.
doi:10.1371/journal.pone.0035017.g001
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we sought to address this question using primary rat CMs as well
as H9c2 cells, a permanent cell line derived from rat cardiac tissue
that offers a unique in vitro model to study the metabolic activity of
the heart [29,30]. In initial experiments, we found that the protein
levels of HIF-1a were low and were not changed by microtubule
interference in normoxic CMs and H9c2 cells (Figure S1).
Additionally, our previous results indicated that the levels of
HIF-1a had no differences in normoxic CMs treated with or
without microtubule interfering agents [7]. Therefore, we focused
on the intracellular responses under hypoxia environment in this
study.
Microtubule-associated proteins, as microtubule regulators,
have the ability to polymerize and stabilize microtubules [31]. In
CMs and H9c2 cells, MAP4 represents the major MAP subtype
Figure 2. Involvement of pVHL in the regulation of HIF-1a
following microtubule alteration. (A, C) CMs and H9c2 cells were
transfected with pVHL recombinant adenovirus or pVHL-siRNA adeno-
virus before treatment with microtubule-interfering agents (paclitaxel
and colchicine) prior to hypoxia. Western blots are shown for HIF-1a in
the microtubule-altered hypoxic CMs and H9c2 cells. H, hypoxia; H+P,
hypoxia and paclitaxel; H+P+pVHL, hypoxia+paclitaxel+pVHL overex-
pression; H+C, hypoxia+colchicine; H+C+pVHL, hypoxia+colchici-
ne+pVHL overexpression; H+P+siRNA, hypoxia+paclitaxel+transfected
for pVHL-siRNA; H+C+siRNA; hypoxia+colchicine+transfected for pVHL-
siRNA; H+GFP, hypoxia and GFP transfection (as a negative control of
pVHL transfection or pVHL-siRNA). (B, D) Graphs represent the
mean6SD (n=5) of the relative integrated signal. DP,0.05 vs. H group
(hypoxia); *P,0.05 vs.H+T group; **P,0.05 vs.H+C group.
doi:10.1371/journal.pone.0035017.g002
Figure 3. Microtubule network depolymerization of hypoxic
cardiomyocytes activated p38/MAPK signaling pathway. Rep-
resentative Western blots (A) and data summary of phospho-p38 (p-
p38) (B) and p38 (C) in the microtubule-altered CMs and H9c2 cells
under hypoxic conditions. H, hypoxia; H+P, hypoxia+paclitaxel;
H+MAP4, hypoxia+MAP4 overexpression; H+HK1, hypoxia+a HK plas-
mid (as a negative control of MAP4 transfection); H+C, hypoxia+colchi-
cine; H+siRNA, hypoxia+transfection of MAP4-siRNA; H+HK2, hypoxia+a
HK plasmid (as a negative control of MAP4-siRNA). Graph represents the
mean6SD (n=5) of the relative gray values. DP,0.05 vs. H group.
doi:10.1371/journal.pone.0035017.g003
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microtubules [7,10]. Likewise, we also found that overexpression
of MAP4 stabilizes microtubules, and vice versa (Figure 1). To
better observe the changes of the downstream signal molecules
following microtubule network alteration, we used the microtu-
bule-stabilizing agent paclitaxel and the microtubule-depolymer-
izing agent colchicine.
HIF-1a is a transcription factor that modulates the cellular
responses to hypoxia [32]. Among its transcriptional targets are
genes that stimulate erythropoiesis, angiogenesis and intracellular
metabolism [33]. It has been demonstrated that microtubule
network alteration leads to change in the protein levels of HIF-1a
[7–9,34]. Our previous study found that microtubular structural
changes regulate the protiein levels of HIF-1a but not mRNA
levels of HIF-1a in the CMs during early stages of hypoxia.
Stabilizing microtubular structures of hypoxic CMs increases HIF-
1a expression, while microtubular structure breakdown decreased
it [7].
pVHL is a component of an E3 ubiquitin protein-ligase
complex that targets HIF-1a for degradation by the ubiquitin-
proteasome pathway [15–17,35,36]. pVHL is known to associate
with at least four other partners: elongin B, elongin C, Cullin-2,
and Rbx1 [37]. The pVHL/HIF-1a interaction within the
cytoplasmic compartment requires hydroxylation of two prolyl
residues (Pro402 and Pro564) in HIF-1a by prolyl-hydroxylases
(PHDs or EGLNs) [20,38]. Under the normoxic condition, pVHL
ubiquitinates HIF-1a and consequently targets HIF-1a to the 26S
proteasome for degradation [39]. However, in hypoxic cells HIF-
1a escapes from degradation because of the inactivation of EGLNs
[19,20,40]. Among those studies reported in the literature that
have analyzed pVHL/HIF-1a interactions in hypoxic cells, none
has investigated the effect of pVHL change on HIF-1a expression
in CMs.
In hypoxic CMs and H9c2 cells, we revealed that microtubular
stabilization or breakdown changed the expression of pVHL,
which was inversely related to the protein levels of HIF-1a.
Moreover, HIF-1a protein levels increased in microtubule altered-
hypoxic cells in which the expression of pVHL was low.
Accordingly, HIF-1a decreased when pVHL was overexpressed
(Figure 2). These results demonstrated that pVHL contributes to
the microtubule network alteration-induced regulation of HIF-1a
in hypoxic CMs and H9c2 cells, although the affinity of HIF-1a
toward the pVHL decreased in hypoxic cells. Recently, del Peso
and colleagues [41] showed that the pVHL/HIF pathway
regulated the transcription of EGLNs genes in response to low
oxygen, suggesting that EGLNs might be involved in the process of
microtubule network alteration-induced regulation of HIF-1a.
Interestingly, we found that microtubule alteration induced
change in phospho-p38, which was positively related to the levels
of pVHL in hypoxic CMs and H9c2 cells. Furthermore,
accumulating data indicate that the p38/MAPK pathway is
involved in the intracellular signaling events triggered by
microtubule-interfering agents [22–24]. Accordingly, we pharma-
cologically inhibited p38/MAPK with SB203580 and overex-
Figure 4. Effect of the p38/MAPK inhibitor, SB203580, on pVHL
in the microtubule-altered hypoxic cardiomyocytes. CMs and
H9c2 cells pretreated with microtubule-interfering agents (paclitaxel
and colchicine) were incubated with or without SB203580 (SB) prior to
hypoxia. (A) Western blots are shown for pVHL. (B) Graph represents the
mean6SD (n=5) of the relative integrated signal. DP,0.05 vs.H group
(hypoxia);*P,0.05 vs.H+T group;**P,0.05 vs.H+C group.
doi:10.1371/journal.pone.0035017.g004
Figure 5. Effect of MKK (Glu) overexpression on pVHL in the
microtubule-altered hypoxic CMs and H9c2 cells. Cells were
transfected with MKK recombinant adenovirus (MKK) before treatment
with microtubule-interfering agents (paclitaxel and colchicine) prior to
hypoxia. (A) Western blots are shown for pVHL. (B) Graph represents the
mean6SD (n=5) of the relative integrated signal. DP,0.05 vs.H group
(hypoxia); *P,0.05 vs.H+T group; **P,0.05 vs.H+C group.
doi:10.1371/journal.pone.0035017.g005
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observe the change of pVHL in hypoxic CMs and H9c2 cells
pretreated with microtubules-interfering agents. We found that
p38/MAPK inactivation down-regulated the expression of pVHL,
while p38/MAPK activation up-regulated it. These findings
suggests that the p38/MAPK pathway is involved in the process
of pVHL change induced by microtubule network alteration. It
has been reported that phosphorylation of pVHL by CK2 and
ubiquitin/SUMO modification of pVHL may regulate VHL
protein stability [42–44], but it is not clear if p38/MAPK interacts
with pVHL directly or indirectly. Future studies are expected to
reveal the details of this process.
The microtubule network participates in a multitude of
intracellular signal transduction pathways, including the p38/
MAPK pathway [22,24,45–47]. It has been reported that
phospho-p38 co-immunoprecipitates with MAP4 in both nomoxic
and hypoxic CMs [5]. We found that phospho-p38 co-immuno-
precipitated with a-tubulin, a major component of microtubule, in
hypoxic CMs and H9c2 cells. This finding provides a physically
interaction for microtubule alteration-induced activation of the
p38/MAPK pathway.
In initial experiments, we identified that stabilizing the
microtubule network of hypoxic cardiomyocytes elevates the
protein contents of HIF-1a, thus promoting glycolysis and ATP
levels, which enhanced the survival of hypoxic CMs [7]. In this
study, we also found that the microtubule network stability was
positively related to the cell viability of hypoxic CMs and H9c2
cells, accompanied by the up-regulation of HIF-1a. Coincidently,
pVHL-siRNA transduction or pretreatment with SB203580
significantly increased hypoxic cells survival. In contrast, overex-
pression of pVHL or MKK6 (Glu) transduction reduced cell
viability of hypoxic CMs and H9c2 cells (Figure S2). These results
further supported the mechanism of HIF-1a regulation revealed in
our present study.
Taken together, we observed that in both hypoxic CMs and
H9c2 cells, microtubule network stabilization downregulated
pVHL by inactivating the p38/MAPK pathway, which in turn
lead to increased levels of HIF-1a. Conversely, microtubule
network breakdown upregulated pVHL-mediated degradation of
HIF-1a through activation of the p38/MAPK pathway.
These findings provide new insights into the molecular
mechanism of HIF-1a protein change in CMs regulated by
microtubule network alteration during early hypoxia. HIF-1a is a
key regulator of the molecular hypoxic response, mediating a wide
range of physiological and cellular processes necessary for cells to
adapt to conditions of reduced oxygen [48]. It has been
demonstrated that up-regulation of HIF-1a in cardiomyocytes is
protective against myocardial ischemia in vivo [49,50]. In addition,
Xiao et al. reported that the microtubule stabilizer, taxol, prevents
ischemic ventricular arrhythmias in rats [51]. Our results may
provide a new therapeutic target for regulating HIF-1a that will
help in limiting myocardial injury after myocardial hypoxia.
Materials and Methods
Cell culture
Primary cardiomyocyte culture. Neonatal Sprague-Dawley rats
(1–2 days old) were provided by the Animal Center of the Third
Military Medical University. The animal-based investigations
were designed in accordance with the Guide for the Care and
Use of Laboratory Animals published by the National Institutes
of Health (NIH Pub. No. 85-23, revised 1996), and the entire
project was reviewed and approved by the Animal Experiment
Ethics Committee of the Third Military Medical University(Permit
Number SYXK-CQ-20070002). Rat ventricular muscles were
harvested and digested with trypsin and then cultured according
to the protocols published previously [52,53]. Neo-natal rat
ventricular CMs were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM)-F12 (Hyclone) supplemented with 5-bromode-
oxyuridine (BrdU; 31 mg/L), 10% (vol/vol) heat-inactivated
fetal bovine serum (FBS; Gibco), penicillin G (100 U/ml) and
streptomycin (100 mg/ml) prior to hypoxia treatment. H9c2 cells
were obtained from the Cell Bank of the Chinese Academy of
Sciences. The cells were cultured in DMEM (Hyclone) supple-
mented with 10% FBS, 100 U/ml penicillin G and 100 mg/ml
streptomycin.
Hypoxia treatment and microtubule-interference
A hypoxia model was established as described previously [5].
Briefly, hypoxic conditions were achieved by using an anaerobic
jar (Mitsubishi, Tokyo, Japan) and vacuum glove box (Chunlong,
Lianyungang, China). The serum-free medium was placed in the
vacuum glove box filled with a gas mixture of 94% N2,5 %C O 2,
and 1% O2 overnight and allowed to equilibrate with the hypoxic
atmosphere. All experimental groups were treated for 3 h under
the same hypoxic conditions at 37uC. The p38/MAPK inhibitor,
SB203580(Beyotime) (5 mmol/L), was added to these cultures and
allowed to incubated at 37uC for 30 min before hypoxia treatment
was commenced.
Microtubule-stabilization was acheived by performing an 8 h
pretreatment with 10 mmol/L paclitaxel (Sigma) or transfection of
MAP4 overexpression plasmids prior to hypoxia treatment.
Microtubule depolymerization was achieved by performing an
8 h pretreatment with 10 mmol/L colchicine (Sigma) or transfec-
tion of MAP4 siRNA before hypoxia treatment.
Figure 6. The physical interaction between phospho-p38 and
a-tubulin detected by immunoprecipitation. Hypoxic CMs and
H9c2 cells were pretreated with paclitaxel or colchicine. (A) Hypoxic
CMs; (B) Hypoxic H9c2 cells. Cell extracts were immunoprecipitated by
anti-phospho-p38 and anti-a-tubulin antibodies and then immuno-
blotted with anti-a-tubulin or anti-phospho-p38 antibody. IP, immuno-
precipitation; IB, immunoblotting; IS, isotype.
doi:10.1371/journal.pone.0035017.g006
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PCR-amplified rat MAP4 cDNA or VHL cDNA were
subcloned into pShuttle2 or pShuttle3 vectors (Clontech) to
generate the recombinant shuttle plasmids pShuttle2-MAP4 or
pShuttle3-VHL. The pShuttle2-HK (hexokinase) or pShuttle3-
EGFP (enhanced green fluorescent protein) were used as negative
controls. MKK6 (Glu) recombinant adenoviruses were generously
provided by Dr. Hu (The Third Military Medical University,
Chongqing, China).
Knockdown of MAP4 or pVHL with siRNA in
cardiomyocyte model
Four RNA interference fragments were designed based on rat
MAP4 or pVHL cDNA sequences. The rat MAP4 siRNA
plasmid, Tuball-1, was constructed using the pGensil-1 vector,
and the rat pVHL siRNA plasmid, Tuball-3, was constructed with
the pGensil-2 vector. These plasmids were then used to construct
recombinant adenoviruses respectively. GS1-HK and GS3-EGFP
plasmids were used as negative controls.
Immunofluorescence assay of microtubules
Immunocytochemical staining was performed as described
previously [52,54]. Primary antibody was mouse anti-a-micro-
tubulin (1:100;Abcam), and secondary antibody was fluorescein
isothiocyanate(FITC) -conjugated goat anti-mouse secondary
antibody(1:1000; Sigma-Aldrich,). The nuclei were stained by
4,6-diamidino-2-phenylindole(DAPI; 0.5 mg/ml; Biotium). The
cells were observed and photographed with a Leica TCS SP5
laser confocal scanning microscope.
Western blot analysis
Cells were washed with ice-cold phosphate-buffered saline
(PBS), harvested in 70–200 mLo f1 6 loading buffer on ice, and
homogenized. Lysates were sonicated for 4 s, and separated by
centrifugation at 4uC for 2 min at 140006g. Whole cell extracts
were probed with primary antibodies against rat MAP4
(1:2000;BD Biosciences), pVHL (1:1000;Cell Signaling Technol-
ogy), HIF-1a (1:1000;Chemicon), p38(1:1000; Cell Signaling
Technology, Beverly, MA), phos-pho-p38 (1:1000, Thr180/
Tyr182; Cell SignalingTechnology), and GAPDH (1:5000;Santa
Cruz Biotechnology). GAPDH staining was used as an internal
control. Immunocomplexes were visualized and quantified with an
enhanced chemiluminescence detection kit (Amersham Pharma-
cia,Piscataway, NJ), using horseradish peroxidase-conjugated
secondary antibodies (1:2000; Santa Cruz).The results were
analyzed with the DOC Gel2000 imaging system (Bio-Rad). Each
experiment was repeated twice, and each group was evaluated five
times.
Immunoprecipitation
Cells (60 mm dish) were lysed in 300 ml RIPA buffer containing
2 mM phenylmethylsulfonyl fluoride (PMSF) and a protease
inhibitor cocktail. Anti-rat phospho-p38 antibody or anti-rat a-
microtubulin antibody was incubated with 150 ml of cell lysate for
6 h at 4uC, then the complexes were precipitated with protein A/
G-Sepharose (Santa Cruz Biotechnology) overnight at 4uC. The
precipitates were washed three times with PBS at 4uC and probed
with anti- phospho-p38 or anti-a-microtubulin antibodies using
the Western blotting technique described above.
Statistical analysis
Normal distribution and homoscedasticity tests of the data were
confirmed and one-way ANOVA followed by post-hoc tests was
performed with SPSS 12.0 software. Results are presented as
mean 6 standard deviation (SD), and statistical significance was
set at P,0.05.
Supporting Information
Figure S1 Effects of microtubule network alteration on HIF-1a
protein levels in normoxic cardiomyocytes. (A) HIF-1a protein
expression of normoxic CMs and H9c2 cells under different
microtubule interfering treatments. (B) relative protein levels for
HIF-1a quantified for each group.
(TIF)
Figure S2 CMs and H9c2 cells viability were measured using a
cell counting kit (CCK-8; Dojindo Molecular Technologies,
Kumamoto, Japan). (A–D) shows the CMs and H9c2 cells viability
under different experimental treatments. DP,0.05 vs. H(hypoxia)
group.
(TIF)
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